article thumbnail

Putting Humans at the Center of Health Care Innovation

Harvard Business Review

The healthcare industry has long relied on traditional, linear models of innovation – basic and applied research followed by development and commercialization. An alternative emerging at healthcare institutions worldwide is human-centered design and co-creation, a set of approaches that can accelerate and humanize healthcare innovation.

article thumbnail

How RFID Technology Improves Hospital Care

Harvard Business Review

When redesigning the new and expanded emergency room at the Mayo Clinic’s Saint Marys Hospital in Rochester, Minnesota, Mayo leaders didn’t just want to add more rooms and square feet. The project was launched in 2013, and the RFID system was rolled out in stages starting in the summer of 2015. Insight Center.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Internet Is Finally Forcing Management to Care About People

Harvard Business Review

It includes Mary Parker Follett (1920s), Elton Mayo and Chester Barnard (1930s), Abraham Maslow (1940s), Douglas McGregor (1960s), Peter Drucker (1970s), Peters and Waterman (1980s), Katzenbach and Smith (1990s), and Gary Hamel (2000s). As a result, customers’ expectations are raised.

article thumbnail

Giving Patients an Active Role in Their Health Care

Harvard Business Review

According to a 2015 survey on the patient experience , nearly 30% of patients physically carry x-rays, test results, and other critical health data from one provider’s office to the next. Innovating for Value in Health Care. And 55% say their medical history is missing or incomplete when they visit their doctor. Insight Center.

article thumbnail

Price Gouging and the Dangerous New Breed of Pharma Companies

Harvard Business Review

In 1950 two Mayo Clinic researchers were awarded the Nobel Prize in medicine for discovering ACTH, the active ingredient in Acthar. Since its passage in 1983, the ODA has governed approval of drugs for rare diseases and has incentivized pharmaceutical innovation via multiple tax breaks and seven years of market exclusivity.

Price 15